Compare Abeona Therapeutics Inc (ABEO) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Devon Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Devon Energy Corp trades at $43.21 (market cap $48.92B). The key difference: Devon Energy Corp is far larger — about 131× Abeona Therapeutics Inc's market cap, and Devon Energy Corp pays a 2.45% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DVN | |
|---|---|---|
Market Cap | $373.32M | $48.92B |
Sector | Health | Energy |
52-Week High | $7.23 | $52.07 |
52-Week Low | $4.17 | $31.74 |
Enterprise Value | $228.22M | $55.69B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Devon Energy (DVN) trades at $42.41, up 4.79% on the day, with a bearish technical signal but bullish oscillators. The stock shows strong profitability with a 13.71% net margin and trades at a P/E of 11.24, below sector averages. Recent news highlights activist pressure for asset sales and a pending Q2 2026 earnings report on August 4, 2026.
DVN presents a value opportunity with a consensus price target of $61.60, implying 45% upside, supported by a 71% buy rating from analysts. Risks include oil price volatility, execution of the Coterra merger synergies, and activist investor demands. The company's disciplined capital allocation and strong cash flow generation underpin the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
